• 1
    Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008; 14: 727733.
  • 2
    Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243250.
  • 3
    Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377382.
  • 4
    British Thoracic Society Standards of Care Committee. BTS guidelines for the management of CAP in adults. Thorax 2009;64 (suppl 3):iii 155.
  • 5
    Chalmers JD, Singanayagam A, Akram AR, Choudhury G, Mandal P, Hill AT. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011; 66: 416423.
  • 6
    Chalmers JD, Singanayagam A, Akram AR et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax 2010; 65: 878883.
  • 7
    Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 14521457.
  • 8
    Menéndez R, Martinez R, Reyes S et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; 64: 987992.
  • 9
    Mandell LA, Wunderink RG, Anzueto A et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia. Clin Infect Dis 2007; 44 (suppl 2): S27S72.
  • 10
    Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 12731276.
  • 11
    el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 10(332): 1355.
  • 12
    Choudhury G, Mandal P, Singanayagam A, Akram AR, Chalmers JD, Hill AT. 7 day antibiotic courses have similar efficacy to prolonged courses in severe community acquired pneumonia- a propensity-adjusted analysis. Clin Microbiol Infect 2011; 17: 18521858.
  • 13
    Aliberti S, Peyrani P, Filardo G et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest 2011; 140: 482488.
  • 14
    Capelastegui A, Espana PP, Bilbao A et al. Pneumonia: criteria for patient instability on hospital discharge. Chest 2008; 134: 595600.
  • 15
    Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181: 975982.
  • 16
    Chalmers JD, Taylor J, Mandal P et al. Validation of the IDSA/ATS minor criteria for ICU admission in community-acquired pneumonia patients without major criteria or contraindications to ICU care. Clin Infect Dis 2011; 53: 503511.
  • 17
    Chalmers JD, Singanayagam A, Hill AT. Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax 2008; 63: 698702.
  • 18
    Chalmers JD, Singanayagam A, Hill AT. Predicting the Need for Mechanical Ventilation and/or vasopressor support for young adults admitted with community-acquired pneumonia. Clin Infect Dis 2008; 47: 15711574.
  • 19
    Arnold FW, Brock GN, Peyrani P et al. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2010; 104: 17361743.
  • 20
    Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM 2011; 104: 871879.
  • 21
    Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008; 121: 219225.
  • 22
    Hanley JA, McNeil BJ. A method comparing the areas under receiver operating characteristic curves derived from the same set of cases. Radiology 1983; 148: 839843.
  • 23
    Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 3235.
  • 24
    Coelho L, Póvoa P, Almeida E et al. Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care 2007; 11: R92.
  • 25
    Chalmers JD, Singanayagam A, Scally C, Fawzi A, Murray MP, Hill AT. Risk Factors for complicated parapneumonic effusion and empyema on presentation to hospital with community acquired pneumonia. Thorax 2009; 64: 592597.
  • 26
    Icard P, Fleury JP, Regnard JF et al. Utility of C-reactive protein measurements for empyema diagnosis after pneumonectomy. Ann Thorac Surg 1994; 57: 933936.
  • 27
    Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on Hospital Discharge and the Risk of Adverse Outcomes in Patients With Pneumonia. Arch Intern Med 2002; 162: 12781284.
  • 28
    Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008; 46: 550556.